Literature DB >> 3613873

Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis.

V S Hubbard, M C McKenna.   

Abstract

Patients with cystic fibrosis (CF) and pancreatic insufficiency usually have decreased linoleic and increased oleic, palmitoleic and eicosatrienoic (20:3 omega 9) acids compared to normal values of blood and tissue lipids. These changes are consistent with early essential fatty acid deficiency and are observed despite the regular use of exogenous pancreatic enzyme supplementation. As part of a study to determine the relative role of malabsorption as the etiology for the altered fatty acid status, the change in total plasma fatty acids and in area percent of plasma linoleic acid was determined in CF patients and control subjects following the ingestion of various lipid supplements, including two safflower oil preparations and two structured lipid preparations. Fasting subjects consumed 36 g of lipid in a milkshake containing 15 g of protein and 45 g of carbohydrate. Plasma samples obtained 0, 2, 4, 6 and 8 hr after the meal showed that the CF patients absorbed all preparations when administered with their regular dose of pancreatic enzyme supplement. Comparison of the patterns of increase for total plasma fatty acids and area percent of plasma linoleic acid following the administration of the different lipid supplements in CF patients and control subjects suggests that malabsorption alone is not the cause of the abnormal fatty acid composition in the lipids of CF patients and that increased caloric intake along with consumption of adequate amounts of linoleic acid should improve the linoleic acid status of CF patients; there may be selectively increased metabolism of certain fatty acids from the ingested lipids in the relatively malnourished CF patient compared to control subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3613873     DOI: 10.1007/bf02537273

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  35 in total

1.  Lipolytic activity of human gastric and duodenal juice against medium and long chain triglycerides.

Authors:  M Cohen; R G Morgan; A F Hofmann
Journal:  Gastroenterology       Date:  1971-01       Impact factor: 22.682

Review 2.  Linoleic acid versus linolenic acid: what is essential?

Authors:  B A Bivins; R M Bell; R P Rapp; W O Griffen
Journal:  JPEN J Parenter Enteral Nutr       Date:  1983 Sep-Oct       Impact factor: 4.016

3.  Lingual lipase in cystic fibrosis. Quantitation of enzyme activity in the upper small intestine of patients with exocrine pancreatic insufficiency.

Authors:  C K Abrams; M Hamosh; V S Hubbard; S K Dutta; P Hamosh
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

Review 4.  Lingual and breast milk lipases.

Authors:  M Hamosh
Journal:  Adv Pediatr       Date:  1982

5.  Comparison of the elimination of 10 and 20% TRAVAMULSION lipid emulsion from the blood of beagle dogs.

Authors:  R Cotter; L Martis; F Cosmas; C Taylor; S Young; W B Rowe; R Johnson
Journal:  Am J Clin Nutr       Date:  1985-05       Impact factor: 7.045

6.  Plasma fatty acids in pancreatic cystic fibrosis and liver disease.

Authors:  R Caren; L Corbo
Journal:  J Clin Endocrinol Metab       Date:  1966-04       Impact factor: 5.958

7.  Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation.

Authors:  J D Lloyd-Still; S B Johnson; R T Holman
Journal:  Am J Clin Nutr       Date:  1981-01       Impact factor: 7.045

8.  Energy needs and growth in children with cystic fibrosis.

Authors:  H G Parsons; P Beaudry; A Dumas; P B Pencharz
Journal:  J Pediatr Gastroenterol Nutr       Date:  1983       Impact factor: 2.839

Review 9.  Cystic fibrosis and malnutrition.

Authors:  H P Chase; M A Long; M H Lavin
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

10.  Medium chain triglycerides in parenteral nutrition.

Authors:  D Sailer; M Müller
Journal:  JPEN J Parenter Enteral Nutr       Date:  1981 Mar-Apr       Impact factor: 4.016

View more
  8 in total

1.  Effects of different medium-chain fatty acids on intestinal absorption of structured triacylglycerols.

Authors:  H Mu; C E Høy
Journal:  Lipids       Date:  2000-01       Impact factor: 1.880

2.  Early dietary intervention with structured triacylglycerols containing docosahexaenoic acid. Effect on brain, liver, and adipose tissue lipids.

Authors:  M M Christensen; C E Høy
Journal:  Lipids       Date:  1997-02       Impact factor: 1.880

3.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

4.  Nutritional evaluation of structured lipid containing omega 6 fatty acid synthesized from coconut oil in rats.

Authors:  Reena Rao; Belur R Lokesh
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

5.  Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula.

Authors:  A S Kenler; W S Swails; D F Driscoll; S J DeMichele; B Daley; T J Babineau; M B Peterson; B R Bistrian
Journal:  Ann Surg       Date:  1996-03       Impact factor: 12.969

6.  Absorption of triglycerides with defined or random structure by rats with biliary and pancreatic diversion.

Authors:  M S Christensen; A Müllertz; C E Høy
Journal:  Lipids       Date:  1995-06       Impact factor: 1.880

7.  Enzyme replacement therapy for pancreatic insufficiency: present and future.

Authors:  Aaron Fieker; Jessica Philpott; Martine Armand
Journal:  Clin Exp Gastroenterol       Date:  2011-05-04

8.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.